Association between IL-6 concentration and diabetes-related variables in DM1 patients with and without microvascular complications

Inflammation

Volumn 36, Issue 3, 2013, Pages 723-728

  Wegner, Malgorzata ^a   Araszkiewicz, Aleksandra ^a   Piorunska Stolzmann, Maria ^a   Wierusz Wysocka, Bogna ^a   Zozulinska Ziolkiewicz, Dorota ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

BMI; interleukin 6; lipid profile; microvascular complications; type 1 diabetes

Indexed keywords

CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOSE; INSULIN; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DISEASE COURSE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; PROTEIN BLOOD LEVEL;

ADULT; BLOOD GLUCOSE; BODY MASS INDEX; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DIABETES MELLITUS, TYPE 1; DIABETIC ANGIOPATHIES; FEMALE; HUMANS; INFLAMMATION; INTERLEUKIN-6; MALE; TRIGLYCERIDES;

EID: 84877745117     PISSN: 03603997     EISSN: 15732576     Source Type: Journal    
DOI: 10.1007/s10753-013-9598-y     Document Type: Article

References (39)

1. Abi Khalil, C., R. Roussel, K. Mohammedi, et al. 2012. Cause-specific mortality in diabetes: recent changes in trend mortality. Eur J Prev Cardiol 19: 374-381.
2. Brownlee, M. 2001. Biochemistry and molecular cell biology of diabetic complications. Nature 414: 813-820.
3. Wegner, M., A. Araszkiewicz, A. Pioruńska-Mikołajczak, et al. 2009. The evaluation of IL-12 concentration, PAF-AH, and PLA(2) activity in patients with type 1 diabetes treated with intensive insulin therapy. Clinical Biochemistry 42: 1621-1627.
4. Marcovecchio, M.L., R.N. Dalton, A.T. Prevost, et al. 2009. Prevalence of abnormal lipid profiles and the relationship with the development of microalbuminuria in adolescents with type 1 diabetes. Diabetes Care 32: 658-663.
5. Aguiar, L.G., N.R. Villela, and E. Bonskela. 2007. Microcirculation in diabetes implications for chronic complications and treatment of the disease. Arg Bras Endorcrinol Metabol 51: 204-211.
6. Devaraj, S., A.T. Cheung, I. Jialal, et al. 2007. Evidence of increased inflammation and microcirculatory abnormalities in patients with type 1 diabetes and their role in microvascular complications. Diabetes 56: 2790-2796.
7. Astrup, A.S., L. Tarnow, L. Pietraszek, et al. 2008. Markers of endothelial dysfunction and inflammation in type 1 diabetic patients with or without diabetic nephropathy followed for 10 years. Diabetes Care 31: 1170-1176.
8. Croker, B.A., H. Kiu, M. Pellegrini, et al. 2012. IL-6 promotes acute and chronic inflammatory disease in the absence of SOCS3. Immunology and Cell Biology 90: 124-129.
9. Waetzig, G.H., and S. Rose-John. 2012. Hitting a complex target: an update on interleukin-6trans-signalling. Expert Opinion on Therapeutic Targets 16: 225-236.
10. Mihara, M., M. Hashizume, H. Yoshida, et al. 2012. IL-6/IL-6 receptor system and its role in physiological and pathological conditions. Clinical Science 122: 143-159.
11. Gabay, C. 2006. Interleukin-6 and chronic inflammation. Arthritis Research & Therapy 8(Suppl 2): 3.
12. Kulseng, B., L. Vatten, and T. Espevik. 1999. Soluble tumor necrosis factor receptors in sera from patients with insulin-dependent diabetes mellitus: relations to duration and complications of disease. Acta Diabetologica 36: 99-105.
13. Targher, G., L. Zenari, L. Bertolini, et al. 2001. Elevated levels of interleukin-6 in young adults with type 1 diabetes without clinical evidence of microvascular and macrovascular complications. Diabetes Care 24: 956-957. Letter.
14. Saraheimo, M., A.M. Teppo, C. Forsblom, et al. 2003. Diabetic nephropathy is associated with low-grade inflammation in type 1 diabetic patients. Diabetologia 46: 1402-1407.
15. Jialal I, Kaur H. 2013. The role of toll-like receptors in diabetes-induced inflammation: implications for vascular complications. Current Diabetes Reports (In press)
16. Araszkiewicz, A., D. Zozulinska-Ziolkiewicz, M. Trepinska, et al. 2008. Knowledge after five-day teaching program in intensive insulin therapy performed at the onset of type 1 diabetes influence the development of late diabetic complications. Diabetes Research and Clinical Practice 81: 61-67.
17. American Diabetes Association. 2007. Standards of medical care in diabetes - 2007. Diabetes Care 30: 4-41.
18. Wilkinson, C.P., F.L. Ferris, R.E. Klein, et al. 2003. Global Diabetic Retinopathy Project Group. Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology 110: 1677-1682.
19. KDOQI. 2007. KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. American Journal of Kidney Diseases 49: 12-154.
20. Jeppsson, J.O., U. Kobold, J. Barr, et al. 2002. International Federation of Clinical Chemistry and Laboratory Medicine (IFCC). Approved IFCC reference method for the measurement of HbA1c in human blood. Clinical Chemistry and Laboratory Medicine 40: 78-79.
21. Hartge, M.M., T. Unger, and U. Kintscher. 2007. The endothelium and vascular inflammation in diabetes. Diabetes & Vascular Disease Research 4: 84-88.
22. Fisman, E.Z., and A. Tenenbaum. 2010. The ubiquitous interleukin-6: a time for reappraisal. Cardiovascular Diabetology 11: 9-62.
23. Navarro, J.F., and M. Carmen. 2005. Role of inflammation in diabetic complications. Nephrology, Dialysis, Transplantation 20: 2601-2604.
24. Munch, I.C., M. Larsen, L. Kessel, et al. 2011. Cumulative glycemia and microangiopathy in subjects with impaired glucose regulation in the Inter 99 study. Diabetes Research and Clinical Practice 91: 226-232.
25. Nevado, J., C. Peiró, S. Vallejo, et al. 2005. Amadori adducts activate nuclear factor-kappaB-related proinflammatory genes in cultured human peritoneal mesothelial cells. British Journal of Pharmacology 146: 268-279.
26. Illán-Gómez, F., M. Gonzálvez-Ortega, I. Orea-Soler, et al. 2012. Obesity and inflammation: change in adiponectin, C-reactive protein, tumour necrosis factor-alpha and interleukin-6 after bariatric surgery. Obesity Surgery 22: 950-955.
27. Sommer, G., S. Kralisch, V. Stangl, et al. 2009. Secretory products from human adipocytes stimulate proinflammatory cytokine secretion from human endothelial cells. Journal of Cellular Biochemistry 106: 729-737.
28. Mohamed-Ali, V., S. Goodrick, and A. Rawesh. 1997. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. Journal of Clinical Endocrinology and Metabolism 82: 4196-4200.
29. Greenberg, A.S., R.P. Nordan, J. McIntosh, et al. 1992. Interleukin 6 reduces lipoprotein lipase activity in adipose tissue of mice in vivo and in 3T3-L1 adipocytes: a possible role for interleukin 6 in cancer cachexia. Cancer Research 52: 4113-4116.
30. Campfield, L.A., F.J. Smith, Y. Guisez, et al. 1995. Recombinant mouse OB protein: evidence for a peripheral signal linking adiposity and central neural networks. Science 269: 546-549.
31. Fawaz, L., A.E. Elwan, Y.H. Kamel, et al. 2009. Value of C-reactive protein and IL-6 measurements in type 1 diabetes mellitus. Arch Med Sci 3: 383-390.
32. Nakamura, N., G. Hasegawa, H. Obayashi, et al. 2003. Increased concentration of pentosidine, an advanced glycation end product, and interleukin-6 in the vitreous of patients with proliferative diabetic retinopathy. Diabetes Research and Clinical Practice 61: 93-101.
33. Nalysnyk, L., M. Hernandez-Medina, and G. Krishnarajah. 2010. Glycaemic variability and complications in patients with diabetes mellitus: evidence from a systematic review of the literature. Diabetes, Obesity & Metabolism 12: 288-298.
34. Lau, D.C., B. Dhillon, H. Yan, et al. 2005. Adipokines: molecular links between obesity and atherosclerosis. American Journal of Physiology-Heart and Circulatory Physiology 288: 2031-2041.
35. Georgescu, A., N. Alexandru, E. Andrei, et al. 2012. Circulating microparticles and endothelial progenitor cells in atherosclerosis: pharmacological effects of irbesartan. Journal of Thrombosis and Haemostasis 10: 680-691.
36. Kolluru, G.K., S.C. Bir, and C.G. Kevil. 2012. Endothelial dysfunction and diabetes: effects on angiogenesis, vascular remodeling, and wound healing. Int J Vasc Med 2012: 918267.
37. Jisieike-Onuigbo, N.N., E.I. Unuigbe, O.A. Kalu, et al. 2011. Prevalence of dyslipidemia among adult diabetic patients with overt diabetic nephropathy in Anambra state south-east Nigeria. Nigerian Journal of Clinical Practice 14: 171-175.
38. Dalla Vestra, M., M. Mussap, P. Gallina, et al. 2005. Acute-phase markers of inflammation and glomerular structure in patients with type 2 diabetes. Journal of the American Society of Nephrology 16: 78-82.
39. Marketou, M.E., E.A. Zacharis, S. Koukouraki, et al. 2008. Effect of angiotensin-converting enzyme inhibitors on systemic inflammation and myocardial sympathetic innervation in normotensive patients with type 2 diabetes mellitus. Journal of Human Hypertension 22: 191-196.